$ONTX,,,share price closed Friday at $1.99, then l
Post# of 23083
(Total Views: 277)
Posted On: 06/03/2017 4:10:24 PM
$ONTX,,,share price closed Friday at $1.99, then lost $.04 in AH. It did have a bad volume day, lower than average but I believe it could move higher given the current falling wedge pattern indicated on the daily chart. It just bounced off bottom support. I am watching for a potential strong move upwards. Indicators are turning up. This is a low float stock, which means the stock can move quickly.
Onconova Therapeutics Inc (ONTX) Insider Ramesh Kumar Acquires 23,810 Shares
May 31st, 2017 - By Scott Moore - 0 comments
Onconova Therapeutics logoOnconova Therapeutics Inc (NASDAQ:ONTX) insider Ramesh Kumar bought 23,810 shares of the stock in a transaction dated Wednesday, April 26th. The shares were purchased at an average price of $2.10 per share, with a total value of $50,001.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Onconova Therapeutics Inc (ONTX) traded down 3.65% during mid-day trading on Wednesday, reaching $1.85. The company had a trading volume of 63,889 shares. The stock’s 50-day moving average price is $2.18 and its 200 day moving average price is $2.61. The company’s market capitalization is $17.55 million. Onconova Therapeutics Inc has a 1-year low of $1.78 and a 1-year high of $8.17.
Onconova Therapeutics (NASDAQ:ONTX) last announced its quarterly earnings results on Monday, May 15th. The biopharmaceutical company reported ($1.23) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by $0.27. Onconova Therapeutics had a negative net margin of 73.67% and a negative return on equity of 148.52%. The business had revenue of $0.21 million during the quarter. Equities analysts expect that Onconova Therapeutics Inc will post ($3.30) EPS for the current year.
An institutional investor recently raised its position in Onconova Therapeutics stock. Vanguard Group Inc. raised its stake in shares of Onconova Therapeutics Inc (NASDAQ:ONTX) by 22.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 55,522 shares of the biopharmaceutical company’s stock after buying an additional 10,350 shares during the period. Vanguard Group Inc. owned approximately 0.82% of Onconova Therapeutics worth $169,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 20.59% of the company’s stock.
A number of research firms have recently commented on ONTX. Maxim Group set a $6.00 target price on Onconova Therapeutics and gave the company a “buy” rating in a research report on Monday, March 27th. Laidlaw began coverage on Onconova Therapeutics in a research report on Thursday, April 27th. They issued a “buy” rating and a $10.00 price target for the company.
Onconova Therapeutics Company Profile:
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agent designed to work against specific cellular pathways that are important to cancer cells.
Onconova Therapeutics Inc (ONTX) Insider Ramesh Kumar Acquires 23,810 Shares
May 31st, 2017 - By Scott Moore - 0 comments
Onconova Therapeutics logoOnconova Therapeutics Inc (NASDAQ:ONTX) insider Ramesh Kumar bought 23,810 shares of the stock in a transaction dated Wednesday, April 26th. The shares were purchased at an average price of $2.10 per share, with a total value of $50,001.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Onconova Therapeutics Inc (ONTX) traded down 3.65% during mid-day trading on Wednesday, reaching $1.85. The company had a trading volume of 63,889 shares. The stock’s 50-day moving average price is $2.18 and its 200 day moving average price is $2.61. The company’s market capitalization is $17.55 million. Onconova Therapeutics Inc has a 1-year low of $1.78 and a 1-year high of $8.17.
Onconova Therapeutics (NASDAQ:ONTX) last announced its quarterly earnings results on Monday, May 15th. The biopharmaceutical company reported ($1.23) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by $0.27. Onconova Therapeutics had a negative net margin of 73.67% and a negative return on equity of 148.52%. The business had revenue of $0.21 million during the quarter. Equities analysts expect that Onconova Therapeutics Inc will post ($3.30) EPS for the current year.
An institutional investor recently raised its position in Onconova Therapeutics stock. Vanguard Group Inc. raised its stake in shares of Onconova Therapeutics Inc (NASDAQ:ONTX) by 22.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 55,522 shares of the biopharmaceutical company’s stock after buying an additional 10,350 shares during the period. Vanguard Group Inc. owned approximately 0.82% of Onconova Therapeutics worth $169,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 20.59% of the company’s stock.
A number of research firms have recently commented on ONTX. Maxim Group set a $6.00 target price on Onconova Therapeutics and gave the company a “buy” rating in a research report on Monday, March 27th. Laidlaw began coverage on Onconova Therapeutics in a research report on Thursday, April 27th. They issued a “buy” rating and a $10.00 price target for the company.
Onconova Therapeutics Company Profile:
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agent designed to work against specific cellular pathways that are important to cancer cells.
(0)
(0)
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280